Systemic inflammatory response depends on initial stroke severity but is attenuated by successful thrombolysis

Stroke

Volumn 35, Issue 9, 2004, Pages 2128-2133

  Audebert, Heinrich J ^a,b   Rott, Michaela M ^a   Eck, Thomas ^a   Haberl, Roman L ^a  

^a City Hospital Munich Harlaching   (Germany)

^b Abteilung für Neurologie Fachklinikum Brandis   (Germany)

Author keywords

C reactive protein; Cerebral infarction; Inflammation; Leukocytes; Stroke, acute; Temperature; Thrombolysis

Indexed keywords

ALTEPLASE; C REACTIVE PROTEIN; FIBRINOLYTIC AGENT;

ADULT; AGED; ARTICLE; BODY TEMPERATURE; BRAIN INFARCTION SIZE; CEREBROVASCULAR ACCIDENT; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; CORRELATION COEFFICIENT; DISEASE SEVERITY; FEMALE; FIBRINOLYTIC THERAPY; HUMAN; LEUKOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; NUCLEAR MAGNETIC RESONANCE IMAGING; OUTCOMES RESEARCH; PARAMETER; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; SCORING SYSTEM; STROKE; SYSTEMIC INFLAMMATORY RESPONSE SYNDROME;

ACUTE DISEASE; AGED; ANALGESICS, NON-NARCOTIC; BIOLOGICAL MARKERS; BODY TEMPERATURE; BRAIN ISCHEMIA; C-REACTIVE PROTEIN; CASE MANAGEMENT; FEMALE; FEVER; HUMANS; INFLAMMATION; LEUKOCYTE COUNT; MALE; MIDDLE AGED; NECROSIS; PATIENT SELECTION; RECOMBINANT PROTEINS; RETROSPECTIVE STUDIES; SEVERITY OF ILLNESS INDEX; SINGLE-BLIND METHOD; SYSTEMIC INFLAMMATORY RESPONSE SYNDROME; THROMBOLYTIC THERAPY; TISSUE PLASMINOGEN ACTIVATOR; TOMOGRAPHY, X-RAY COMPUTED;

EID: 4344590867     PISSN: 00392499     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.STR.0000137607.61697.77     Document Type: Article

References (43)

1. Kazmierski R, Guzik P, Ambrosius W, Kozubski W. [Leukocytosis in the first day of acute ischemic stroke as a prognostic factor of disease progression]. Wiad Lek. 2001;54:143-151. In Polish.
2. Boysen G, Christensen H. Stroke severity determines body temperature in acute stroke. Stroke. 2001;32:413-417.
3. Schwab S, Spranger M, Aschoff A, Steiner T, Hacke W. Brain temperature monitoring and modulation in patients with severe MCA infarction. Neurology. 1997;48:762-767.
4. Hacke W, Kaste M, Olsen TS, Orgogozo JM, Bogousslavsky J. European Stroke Initiative: recommendations for stroke management. Organisation of stroke care. J Neurol. 2000;247:732-748.
5. Hacke W, Kaste M, Skyhoj OT, Orgogozo JM, Bogousslavsky J. European Stroke Initiative (EUSI) recommendations for stroke management. The European Stroke Initiative Writing Committee. Eur J Neurol. 2000;7:607-623.
6. Kothari RU, Brott T, Broderick JP, Barsan WG, Sauerbeck LR, Zuccarello M, Khoury J. The ABCs of measuring intracerebral hemorrhage volumes. Stroke. 1996;27:1304-1305.
7. Kogure K, Yamasaki Y, Matsuo Y, Kato H, Onodera H. Inflammation of the brain after ischemia. Acta Neurochir Suppl (Wien). 1996;66:40-43.
8. Davalos A, Castillo J, Pumar JM, Noya M. Body Temperature and fibrinogen are related to early neurological deterioration in acute ischemic stroke. Cerebrovasc Dis. 1997;7:64-69.
9. Castillo J, Davalos A, Noya M. Aggravation of acute ischemic stroke by hyperthermia is related to an excitotoxic mechanism. Cerebrovasc Dis. 1999;9:22-27.
10. Castillo J, Davalos A, Marrugat J, Noya M. Timing for fever-related brain damage in acute ischemic stroke. Stroke. 1998;29:2455-2460.
11. Georgilis K, Plomaritoglou A, Dafni U, Bassiakos Y, Vemmos K. Aetiology of fever in patients with acute stroke. J Intern Med. 1999;246:203-209.
12. Reith J, Jorgensen HS, Pedersen PM, Nakayama H, Raaschou HO, Jeppesen LL, Olsen TS. Body temperature in acute stroke: relation to stroke severity, infarct size, mortality, and outcome. Lancet. 1996;347:422-425.
13. Fukuda H, Kitani M, Takahashi K. Body temperature correlates with functional outcome and the lesion size of cerebral infarction. Acta Neurol Scand. 1999;100:385-390.
14. Wang Y, Lim LL, Levi C, Heller RF, Fisher J. Influence of admission body temperature on stroke mortality. Stroke. 2000;31:404-409.
15. Hajat C, Hajat S, Sharma P. Effects of poststroke pyrexia on stroke outcome: a meta-analysis of studies in patients. Stroke. 2000;31:410-414.
16. Jorgensen HS, Reith J, Nakayama H, Kammersgaard LP, Raaschou HO, Olsen TS. What determines good recovery in patients with the most severe strokes? The Copenhagen Stroke Study. Stroke. 1999;30:2008-2012.
17. Grau AJ, Buggle F, Schnitzler P, Spiel M, Lichy C, Hacke W. Fever and infection early after ischemic stroke. J Neurol Sci. 1999;171:115-120.
18. Azzimondi G, Bassein L, Nonino F, Fiorani L, Vignatelli L, Re G, D'Alessaadro R. Fever in acute stroke worsens prognosis. A prospective study. Stroke. 1995;26:2040-2043.
19. Maier CM, Ahern K, Cheng ML, Lee JE, Yenari MA, Steinberg GK. Optimal depth and duration of mild hypothermia in a focal model of transient cerebral ischemia: effects on neurologic outcome, infarct size, apoptosis, and inflammation. Stroke. 1998;29:2171-2180.
20. Audebert H, Pellkofer S, Wimmer ML, Haberl RL. Progression in lacunar stroke is related to elevated acute phase parameters. Eur Neurol. 2004;51:125-131.
21. Muir KW, Weir CJ, Alwan W, Squire IB, Lees KR. C-reactive protein and outcome after ischemic stroke. Stroke. 1999;30:981-985.
22. Di Napoli M, Papa F, Bocola V. C-reactive protein in ischemic stroke: an independent prognostic factor. Stroke. 2001;32:917-924.
23. Canova CR, Courtin C, Reinhart WH. C-reactive protein (CRP) in cerebrovascular events. Atherosclerosis. 1999;147:49-53.
24. Di Napoli M, Papa F, Bocola V. Prognostic influence of increased C-reactive protein and fibrinogen levels in ischemic stroke. Stroke. 2001;32:133-138.
25. Akopov SE, Simonian NA, Grigorian GS. Dynamics of polymorphonuclear leukocyte accumulation in acute cerebral infarction and their correlation with brain tissue damage. Stroke. 1996;27:1739-1743.
26. Hallenbeck JM, Dutka AJ, Tanishima T, Kochanek PM, Kumaroo KK, Thompson CB, Obrenovitch TP, Contreras TJ. Polymorphonuclear leukocyte accumulation in brain regions with low blood flow during the early postischemic period. Stroke. 1986;17:246-253.
27. Wang PY, Kao CH, Mui MY, Wang SJ. Leukocyte infiltration in acute hemispheric ischemic stroke. Stroke. 1993;24:236-240.
28. Elneihoum AM, Falke P, Axelsson L, Lundberg E, Lindgarde F, Ohlsson K. Leukocyte activation detected by increased plasma levels of inflammatory mediators in patients with ischemic cerebrovascular diseases. Stroke. 1996;27:1734-1738.
29. Kochanek PM, Hallenbeck JM. Polymorphonuclear leukocytes and monocytes/macrophages in the pathogenesis of cerebral ischemia and stroke. Stroke. 1992;23:1367-1379.
30. Vila N, Filella X, Deulofeu R, Ascaso C, Abellana R, Chamorro A. Cytokine-induced inflammation and long-term stroke functional outcome. J Neurol Sci. 1999;162:185-188.
31. Galante A, Silvestrini M, Stanzione P, Pietroiusti A, Baldoni F, Domenici B, Bernardi G. Leucocyte aggregation in acute cerebrovascular disease. Acta Neurol Scand. 1992;86:446-449.
32. Silvestrini M, Pietroiusti A, Troisi E, Franceschelli L, Piccolo P, Magrini A, Bernardi G, Galante A. Leukocyte count and aggregation during the evolution of cerebral ischemic injury. Cerebrovasc Dis. 1998;8:305-309.
33. Smith CJ, Emsley HC, Gavin CM, Georgiou RF, Vail A, Barberan EM, del Zoppo GJ, Hallenbeck JM, Rothwell NJ, Hopkins SJ, Tyrrell PJ. An early and sustained peripheral inflammatory response in acute ischaemic stroke: relationships with infection and atherosclerosis. J Neuroimmunol. 2003;139:93-101.
34. Carlson NG, Wieggel WA, Chen J, Bacchi A, Rogers SW, Gahring LC. Inflammatory cytokines IL-1 alpha, IL-1 beta, IL-6, and TNF-alpha impart neuroprotection to an excitotoxin through distinct pathways. J Immunol. 1999;163:3963-3968.
35. Castillo J, Leira R. Predictors of deteriorating cerebral infarct: role of inflammatory mechanisms. Would its early treatment be useful? Cerebrovasc Dis. 2001;11(suppl 1):40-49.
36. Castellanos M, Castillo J, Garcia MM, Leira R, Serena J, Chamorro A, Davalos A. Inflammation-mediated damage in progressing lacunar infarctions: a potential therapeutic target. Stroke. 2002;33:982-987.
37. del Zoppo GJ, Becker KJ, Hallenbeck JM. Inflammation after stroke: is it harmful? Arch Neurol. 2001;58:669-672.
38. Whitaker JN. The potential for harm or benefit from inflammatory processes in stroke. Arch Neurol. 2001;58:674.
39. Nagayama M, Niwa K, Nagayama T, Ross ME, Iadecola C. The cyclooxygenase-2 inhibitor NS-398 ameliorates ischemic brain injury in wild-type mice but not in mice with deletion of the inducible nitric oxide synthase gene. J Cereb Blood Flow Metab. 1999;19:1213-1219.
40. Iadecola C, Alexander M. Cerebral ischemia and inflammation. Curr Opin Neurol. 2001;14:89-94.
41. Gidday J, Campbell J, Perez R, Gonzales E, Shah A, Park T. Mechanisms of cyclooxygenase-2 induced brain injury following permanent middle cerebral artery occlusion. Stroke. 2002;33. Abstract.
42. Domoki F, Perciaccante JV, Puskar M, Bari F, Busija DW. Cyclooxygenase-2 inhibitor NS398 preserves neuronal function after hypoxia/ischemia in piglets. Neuroreport. 2001;12:4065-4068.
43. Coimbra C, Drake M, Boris-Moller F, Wieloch T. Long-lasting neuroprotective effect of postischemic hypothermia and treatment with an anti-inflammatory/antipyretic drug. Evidence for chronic encephalopathic processes following ischemia. Stroke. 1996;27:1578-1585.